Advanced search
Publication Cover
Future Oncology Volume 12, 2016 - Issue 4
Submit an article Journal homepage
158
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Effective Targeting of Colorectal Cancer Cells using TORC1/2 Kinase Inhibitors In Vitro and In Vivo

Jie Zhang1 The Affiliated Hospital of Nantong University, Nantong226001, China;2 School of Medicine, Nantong University, Nantong226019, China
,
Wen Jiang3 Department of Internal Medicine, The Third People’s Hospital of Nantong, Nantong226001, China
,
Wei Liu4 Department of Orthopedics, The Second Affiliated Hospital of Nantong University, Nantong226001, China
,
Juan-Juan Wu2 School of Medicine, Nantong University, Nantong226019, China
,
Lei Song5 Department of Paediatrics, The Second Affiliated Hospital of Nantong University, Nantong226001, China
,
Ji-Xian Cheng6 Department of Oncological Surgery, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou325001, China
,
Ming Yao1 The Affiliated Hospital of Nantong University, Nantong226001, China
,
Li-Ping Yang2 School of Medicine, Nantong University, Nantong226019, China
&
Deng-Fu Yao1 The Affiliated Hospital of Nantong University, Nantong226001, ChinaCorrespondence[email protected]
 show all
Pages 515-524 | Received 24 Jun 2015, Accepted 01 Sep 2015, Published online: 18 Jan 2016

References

  • Schreuders EH , RucoA, RabeneckLet al. Colorectal cancer screening: a global overview of existing programmes. Gut64(10), 1637–1649 (2015).
  • Yamada A , HorimatsuT, OkugawaYet al. Serum miR-21, miR-29a and miR-125b are promising biomarkers for the early detection of colorectal neoplasia. Clin. Cancer. Res.21(18), 4234–4242 (2015).
  • De Mattia E , CecchinE, ToffoliG. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy. Drug Resist. Updat.20, 39–70 (2015).
  • Yu K , Toral-BarzaL, ShiCet al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res.69(15), 6232–6240 (2009).
  • Engelman JA , LuoJ, CantleyLC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet.7(8), 606–619 (2006).
  • Samuels Y , EricsonK. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol.18(1), 77–82 (2006).
  • Wee S , JaganiZ, XiangKXQet al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res.69(10), 4286–4293 (2009).
  • Martelli AM , TabelliniG, BortulRet al. Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histol. Histopathol.20(1), 239–252 (2005).
  • Yap TA , GarrettMD, WaltonMI, RaynaudF, De BonoJS, WorkmanP. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol.8(4), 393–412 (2008).
  • Guertin DA , SabatiniDM. Defining the role of mTOR in cancer. Cancer Cell12(1), 9–22 (2007).
  • Abraham RT , EngCH. Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin. Ther. Targets12(2), 209–222 (2008).
  • Guertin DA , SabatiniDM. The Pharmacology of mTOR Inhibition. Sci. Signal.2(67), pe24 (2009).
  • Janes MR , LimonJJ, SoLet al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat. Med.16(2), 205–213 (2010).
  • Gao CF , XieQ, SuYLet al. Proliferation and invasion: plasticity in tumor cells. Proc. Natl Acad. Sci. USA102(30), 10528–10533 (2005).
  • Feldman ME , ApselB, UotilaAet al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol.7(2), e38 (2009).
  • Crowley-Weber CL , PayneCM, Gleason-GuzmanMet al. Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate. Carcinogenesis23(12), 2063–2080 (2002).
  • Zhang G , GurtuV, KainSR, YanG. Early detection of apoptosis using a fluorescent conjugate of annexin V. Biotechniques23(3), 525–531 (1997).
  • Garcia-Martinez JM , MoranJ, ClarkeRGet al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J.421(1), 29–42 (2009).
  • Thoreen CC , KangSA, ChangJWet al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem.284(12), 8023–8032 (2009).
  • Atreya CE , DuckerGS, FeldmanME, BergslandEK, WarrenRS, ShokatKM. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest. New Drugs30(6), 2219–2225 (2012).
  • Cai Z , KeJ, HeXet al. Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer. Ann. Surg. Oncol.21(1), 179–188 (2014).
  • Vidal SJ , Rodriguez-BravoV, GalskyM, Cordon-CardoC, Domingo-DomenechJ. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene33(36), 4451–4463 (2014).
  • Roy R , WillanPM, ClarkeR, FarnieG. Differentiation therapy: targeting breast cancer stem cells to reduce resistance to radiotherapy and chemotherapy. Breast Cancer Res.12, S2–S2 (2010).
  • Wang Q , WeiF, LiCet al. Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma. PLoS ONE8(8), e73175 (2013).
  • Ducker GS , AtreyaCE, SimkoJPet al. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene33(12), 1590–1600 (2014).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.